Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.

Repeated ketamine administration in male rats produces schizophrenia-like symptoms and alters glutamatergic and dopaminergic activity, mainly in the prefrontal cortex and dorsomedial striatum, through a bidirectional pattern. These changes are accompanied by glutamatergic/GABAergic deviations and impaired function of parvalbumin- and cholecystokinin-positive interneurons, indicating an excitation/inhibition imbalance. Cannabidiol (CBD) counteracted the schizophrenia-like behavioral phenotype, reversed prefrontal abnormalities and ventral hippocampal E/I deficits, and partially modulated dorsostriatal dysregulations. The findings suggest CBD's antipsychotic action involves region-specific modulations in corticohippocampal and corticostriatal circuitry, pointing to potential therapeutic strategies focused on restoring E/I balance.

Study at a glance

Abstract

Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been linked to antipsychotic effects with unclear mechanistic basis. Therefore, this study aims to clarify the neurobiological substrate of repeated KET administration model and to evaluate CBD's antipsychotic potential and neurobiological basis. CBD-treated male rats with and without prior repeated KET administration underwent behavioral analyses, followed by multilevel analysis of different brain areas including dopaminergic and glutamatergic activity, synaptic signaling, as well as electrophysiological recordings for the assessment of corticohippocampal and corticostriatal network activity. Repeated KET model is characterized by schizophrenia-like symptomatology and alterations in glutamatergic and dopaminergic activity mainly in the PFC and the dorsomedial striatum (DMS), through a bi-directional pattern. These observations are accompanied by glutamatergic/GABAergic deviations paralleled to impaired function of parvalbumin- and cholecystokinin-positive interneurons, indicative of excitation/inhibition (E/I) imbalance. Moreover, CBD counteracted the schizophrenia-like behavioral phenotype as well as reverted prefrontal abnormalities and ventral hippocampal E/I deficits, while partially modulated dorsostriatal dysregulations. This study adds novel insights to our understanding of the KET-induced schizophrenia-related brain pathology, as well as the CBD antipsychotic action through a region-specific set of modulations in the corticohippocampal and costicostrtiatal circuitry of KET-induced profile contributing to the development of novel therapeutic strategies focused on the ECS and E/I imbalance restoration.